Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
175 EVENTS
Commenced prescription drug sales business in Toyama City, Toyama Prefecture.
Established Takayanagi Pharmaceutical Trading Company, Ltd.
Established a new branch office in Maebashi City, Gunma Prefecture.
Renamed to Fuji Pharmaceutical Ltd.
Converted to a corporation.
Established a branch office in Hino City, Tokyo to expand distribution channels for prescription drug sales business.
Expanded into the southern Kanto region.
Expanded into the Hokuriku region.
Expanded into the northern Kyushu region.
Expanded into the Tokai region.
Expanded into the Tohoku region.
Expanded into the Hokkaido region.
Expanded into the Kinki region.
Expanded into the Chubu region.
Moved headquarters to the current location (4-383 Sakuragi-cho, Omiya-ku, Saitama City, Saitama Prefecture, 330-9508, Japan).
Expanded into the Shikoku region.
Started establishing a regional sales subsidiary.
Expanded into the Southern Kyushu region.
Constructed the Toyama factory in Fuchu Town, Fuku District, Toyama Prefecture (now Fuchu Town, Toyama City).
Commenced in-house production of the comprehensive gastrointestinal medicine 'Fuji GI Medicine'.
Commenced in-house production of the antipyretic analgesic 'New Kaiteki Z'.
Commenced in-house production of the comprehensive cold medicine 'Shin Jikina Granules'.
Established the Fuji Training Center in Fuchu Town, Fuku District, Toyama Prefecture (now Fuchu Town, Toyama City).
Expanded the Toyama factory and began in-house production of drink, eye drop, and ointment preparations.
Established a pharmaceutical research and development division and set up the First Research Institute in Ōmiya City, Saitama Prefecture (now Saitama City).
Constructed the Toyama Second Factory adjacent to the Toyama factory.
Commenced the drugstore business.
Absorbed and merged with Okayama Fuji Pharmaceutical Co., Ltd. and Yamaguchi Fuji Pharmaceutical Co., Ltd.
Commenced manufacturing and sales of medical drugs.
Established the Second Research Institute in Ōmiya City, Saitama Prefecture (now Saitama City) for pharmacological research.
Absorbed and merged with Miyazaki Fuji Pharmaceutical Co., Ltd. and Tosu Fuji Pharmaceutical Co., Ltd.
Absorbed and merged with Tōura Fuji Pharmaceutical Co., Ltd.
Established an automatic rack-type warehouse at the Toyama factory.
Increased capital to 315,459,950 yen through a third-party allotment of capital increase.
Participated in the management of Ooata Drug Co., Ltd.
Established Cosmo Pharmaceutical Co., Ltd.
Expansion of the Toyama factory
Completion of the New Second Research Institute
Absorption merger of Ueda Fuji Pharmaceutical Co., Ltd. and Hidaka Fuji Pharmaceutical Co., Ltd.
Acquisition of all shares of Towa Pharmaceutical Co., Ltd.
Capital participation in Abeer Co., Ltd.
Completion of the head office annex
Capital participation in G.C.C. Ltd.
Establishment of Ohashi Emergency Pharmaceutical Co., Ltd.
Top partner agreement with Omiya Ardija, a club in the Japan Professional Soccer League.
Formation of Fuji Pharmaceutical Union
Capital participation in Rise Co., Ltd.
Capital participation in Sante Drug Co., Ltd. (formerly Yoshikawa Sante)
Acquisition of all shares of Panakeia Pharmaceutical Co., Ltd. (formerly Takao Nakagaku Pharmaceutical)
Joint establishment of Fine Pharmaceutical Co., Ltd.
Acquisition of all shares of Lion Create Co., Ltd.
Capital participation in Kyowa Trading Co., Ltd.
Capital participation in Moriki Co., Ltd.
Establishment of Fact Pharmaceutical Co., Ltd.
Acquisition of the Shikoku regional sales rights from Drag Lion Co., Ltd., and commencement of operations as the Shikoku Division.
Acquisition of all shares of Sasao Pharmacy Co., Ltd.
Capital participation in Lemon Co., Ltd.
Established Lead Pharmaceutical Co., Ltd.
Capital participation in Hoshino Co., Ltd.
Acquired the Okayama region sales rights from Drag Lion Co., Ltd., and commenced operations as the Chūshikoku Business Division.
Acquired all shares of Cosmos 21 Drug Store Co., Ltd.
Acquired all shares of Kirin Drug Store Co., Ltd.
Acquired the sales rights of Taiyo and commenced operations as Just Drug Co., Ltd.
Acquired the sales rights of Inaba and transferred them to Moriki Co., Ltd.
Acquired the sales rights of Orix and commenced operations as Shinsei Orix Co., Ltd.
Acquired all shares of Moriyama Pharmacy Co., Ltd.
Completion of expansion works at the Toyama Second Factory.
Acquired all shares of Tamura Pharmacy Co., Ltd.
Entered into a business partnership and capital participation with Yutaka Pharmacy Co., Ltd.
Acquired all shares of Powers Drug Co., Ltd.
Acquired all shares of Shinoda Pharmacy Co., Ltd.
Absorbed and split the Chūshikoku Business Division, and renamed the company to Chūshikoku Seims Co., Ltd.
Established Medical Cosmos Pharmaceutical Co., Ltd.
Capital participation in Drag Ozone Co., Ltd.
Completion of comprehensive renovation works at the Toyama Factory.
Acquired all shares of Happy Door Co., Ltd.
Acquisition of all businesses of Abeel Co., Ltd.
Start of sales of the renal function test drug "InuRidge® Injection".
Acquisition of all shares of TriX Co., Ltd.
Obtained ISO 14001 certification for the Toyama factory.
Established Shinkou Seikaku Pharmaceutical Co., Ltd.
Acquisition of all shares of Myoujou Pharmaceutical Co., Ltd.
Acquisition of all shares of Taiyodo Pharmaceutical Co., Ltd.
Acquisition of all businesses of Happy Door Co., Ltd.
Capital participation in Drugstore Baigo Co., Ltd.
Acquisition of all shares of Alpha Co., Ltd.
Acquisition of all businesses of Shinoda Pharmacy Co., Ltd.
Capital participation in Shibata Pharmaceutical Co., Ltd.
Established Boso Fuji Pharmaceutical Co., Ltd.
Acquisition of all shares of Uchiyama Pharmaceutical Trading Co., Ltd.
Established Shinpou Pharmaceutical Co., Ltd.
Established New Saitama Pharmaceutical Co., Ltd.
Established Fuji Pharmaceutical Universal Network (Special Subsidiary) Co., Ltd.
Moriki Co., Ltd. absorbed Tamura Co., Ltd. and Powers Drug Co., Ltd.
Acquisition of all shares of Kyousei Pharmaceutical Industry Co., Ltd.
Established Shin Kyousei Pharmaceutical Co., Ltd.
Opened the Omiya headquarters and consolidated corporate functions.
Alpha Co., Ltd. acquired part of Lion Create Co., Ltd.'s business and changed its name to Tohoku Seims Co., Ltd.
Chugoku Shikoku Seims Co., Ltd. absorbed Drugstore Cosmos 21 Co., Ltd. and changed its name to West Japan Seims Co., Ltd.
Established Tokai Seims Co., Ltd.
Just Drug Co., Ltd. absorbed Shibata Pharmaceutical Co., Ltd. and changed its name to Kanto Seims Co., Ltd.
Acquired all shares of Nozaki Pharmaceutical Co., Ltd.
Established a local subsidiary, Fukata Meiken Trading Co., Ltd., in Shanghai.
Kyoei Pharmaceutical Industry Co., Ltd. absorbed Panakeia Pharmaceutical Co., Ltd. and changed its name to Panakeia Pharmaceutical Co., Ltd.
Smile Drug Co., Ltd. absorbed YS Trading Co., Ltd.
Fuso Fuji Pharmaceutical Co., Ltd. absorbed Chiba Fuji Pharmaceutical Co., Ltd. and changed its name to Chiba Fuji Pharmaceutical Co., Ltd.
Noble Pharmaceutical Co., Ltd. changed its name to Neo Pharmaceutical Co., Ltd.
New Saitama Pharmaceutical Co., Ltd. changed its name to Fuji Pharmaceutical Sales Co., Ltd.
Opened the first Drug Seims (Imis) store in Shanghai.
Invested capital in Samoa Bio Inc.
Changed the shareholder register custodian to Mizuho Trust Bank.
Entered a capital and business alliance with Ost Japan Group Co., Ltd.
Absorbed Lion Create Co., Ltd.
Absorbed Miyas Fuji Land and Building Co., Ltd. and Create Ltd.
Signed a contract with male professional tennis player Uchiha Kaito.
Obtained manufacturing and sales approval for the hyperuricemia treatment drug 'Topiric® tablets'.
Commenced sales of the hyperuricemia treatment drug 'Topiric® tablets'.
Absorbed and merged with Dragestore Baigo Co., Ltd.
Acquired all shares of Kusuri no Tsurumido Co., Ltd.
Acquired all shares of Yutaka Pharmacy Co., Ltd.
Signed sponsorship agreements with professional female golfers Ayaka Watanabe and Mitsuri Fujita.
Initiated long-term prescriptions for 'Topiric® tablets'.
Absorbed and merged with Kanto Seims Co., Ltd.
Signed a sponsorship agreement with professional female tennis player Kurumi Nara.
Completion of the new factory of Panakeia Pharmaceutical Co., Ltd.
Absorbed and merged with Tohoku Seims Co., Ltd. and S-Route Co., Ltd.
Launched the support program for junior female tennis players, 'Fuji Pharmaceutical Seims World Challenge Program', and held the first 'Fuji Pharmaceutical Seims Girls Cup' to select participants.
Acquired all shares of Kyūmeidō Co., Ltd.
Nippon Seiei Co., Ltd. inherits and acquires the pharmacy dispensing business of a subsidiary of the Health Science Group Headquarters.
Hosted the first edition of the International Tennis Federation-sanctioned tournament 'Fuji Pharmaceutical Seims Women's Cup'.
Absorbed and merged with Kyushu Seims Co., Ltd. and Kyūmeidō Co., Ltd.
Withdrawn from Shanghai.
Applied for manufacturing and sales approval in Japan for the gout and hyperuricemia treatment drug 'FYU-981' (generic name: Doxinurad).
Hosted the third ITF Circuit 'Fuji Pharmaceutical Seims Women's Cup' tournament.
Liquidated Zhonghua Shengyi Technology Co., Ltd. (Samoa Bio Inc.).
MoriKi Co., Ltd. absorbs and merges with Tohoku Seims Co., Ltd.
Acquires all shares of Amiha Pharmacy Co., Ltd.
Signs a contract with professional female tennis player Sato Kumanari.
Signs a sponsorship contract with professional female golfer Haruka Morita.
Accepts inspection at the Toyama Second Factory for obtaining FDA certification.
Obtains manufacturing and sales approval in Japan for the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)'.
Signs a license agreement for development and sales of the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)' in China.
Absorbs and merges with Smile Drug Co., Ltd.
Acquires all shares of Taiyo-do Co., Ltd.
Establishes Tokyo headquarters in Chiyoda-ku, Tokyo, and relocates headquarters functions.
Launches sales of the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)'.
Transfers part of the rights and obligations related to the insurance pharmacy business of Nohin Co., Ltd. to MoriKi Co., Ltd. through a corporate split.
Transfers all rights and obligations except those transferred in the above corporate split, and absorbs and merges with Nohin Co., Ltd.
Announces exclusive license agreement with Fortress Biotech, Inc. for development and sales of the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)' in North America and Europe.
Seims signs a top partner agreement with Omiya Ardija Ventus, which entered the first Japanese women's professional soccer league 'WE League' in September 2021.
Formulates the Fuji Pharmaceutical Group slogan.
Signs a license agreement with Eisai for development and sales of the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)' in five ASEAN countries.
Subsidiary Yutaka Pharmacy Co., Ltd. absorbs and merges with Taiyo-do Co., Ltd.
Signs an exclusive license agreement with Shengda Chemical Pharmaceutical Co., Ltd. for development and sales of 'Yuris® tablets' in Taiwan.
Certified as a 'White 500' health management excellence corporation.
Signed a sponsorship contract with female professional golfer Ayako Yamada.
Signed a comprehensive cooperation agreement on health promotion with Uonuma City, Niigata Prefecture, and began initiatives in collaboration with local governments starting with this.
Received Silver certification for the PRIDE Index, an evaluation metric for LGBTQ+ and other sexual minorities.
Expanded the territory covered by the exclusive license agreement with Fortress Biotech, Inc. for the development and sale of Yuris® tablets to include the Middle East and North Africa, including Turkey.
Certified as a White 500 health management excellence corporation for the second consecutive year.
Initiated health management support services for companies that contract placement drugs.
Started handling disaster prevention supplies for companies that contract placement drugs.
Introduced "Same Touch" in all Fuji Pharmacy Group drugstores except Drag Yutaka.
Relocated the First Research Institute to Shonan Health Innovation Park (1-26-1 Murouka Higashi 2-chome, Fujisawa City, Kanagawa Prefecture).
Received Gold certification for the PRIDE Index 2023, the highest evaluation for LGBTQ+ and other sexual minorities.
In response to Kyoha Shoji Co., Ltd.'s share buyback, the company withdrew from the Fuji Pharmacy Group.
Certified as a White 500 health management excellence corporation for the third consecutive year.
Signed a membership contract with tennis player Sakura Saito.
Relocated the Omiya headquarters to AddGrace Omiya (1-398-1 Sakuragicho, Omiya-ku, Saitama City, Saitama Prefecture).
Made Rakuten Point Card available at Fuji Pharmacy Group drugstores such as "Seimus".
Certified as "Kurumin Plus" by the Ministry of Health, Labour and Welfare.
Obtained approval in Thailand for the gout and hyperuricemia drug "Dochinurad".
Won Gold, the highest rating for two consecutive years, in the PRIDE Index 2024 for LGBTQ+ and other sexual minorities.
Obtained approval in China for the gout indication associated with hyperuricemia for the gout and hyperuricemia drug "Dochinurad".
§07
News
11 ARTICLES
Warm Herbal Ginger November 1 Release
Fuji Pharmaceutical will launch the powdered beverage 'Warm Herbal Ginger' from the health food brand 'Delicharm' in a limited quantity on November 1, 2026. It is a yuzu-flavored product that combines ginger, Hihatsu, hesperidin, and rough chamomile, dissolved in hot water. In addition to prescription drug sales, it will be tested for sale in some Fuji Pharmaceutical Group drugstore locations.
Fuji Eye AL Premium new release November 1
Fuji Pharmaceutical will launch the second-class drug 'Fuji Eye AL Premium' from the eye drop brand 'Fuji Eye' on November 1, 2026. It contains five active ingredients that suppress the release and action of histamine and soothe inflammation, providing effective relief from itchy eyes caused by pollen and house dust.
From November 1, 2026 to December 31, 2026, Fuji Pharmaceutical will hold the "Winter Appreciation Campaign." Purchases of 2,000 yen or more including tax, with eligible products, can be entered via LINE. 570 lucky winners will receive a QUO Card Pay (up to 10,000 yen) usable at Fuji Pharmaceutical Group drugstores. Eligible products can be purchased at the group's drugstores, official online store, or in-store pharmacies.
Fuji Pharmaceutical to Relaunch Fuji's Green Juice as a Foods with Function Claims Product
Fuji Pharmaceutical Co., Ltd. will relaunch Fuji's Green Juice, part of its Delicharm health food brand, as a Foods with Function Claims product on October 1, 2026. The green juice contains six ingredients, vitamins, and dietary fiber, and will be available through Fuji Pharmaceutical's sales channels.
Fuji Yakuhin to Launch New Laforth Functional Food “Kore脂 Down W”
Fuji Yakuhin announced that it will launch Kore脂 Down W, a new food with functional claims under its Laforth supplement brand, on September 1, 2026. It is intended for people concerned about obesity, high BMI, or high LDL cholesterol.
Tsukai Enema for Constipation to Launch on August 1
Fuji Yakuhin announced that its Tsukai® Enema line, for relief from difficult constipation, will launch on Saturday, August 1, 2026. It will be available in three sizes: 10 g, 30 g, and 40 g, at drugstores including SEIMS and through the official online store.
Fuji Time AQUA White Grape Mix to Launch in Limited Quantities
Fuji Yakuhin will release Fuji Time AQUA White Grape Mix, a limited-edition flavor of its apple vinegar drink in the Fuji Time line under the Delicharm health food brand, on Saturday, August 1. The product line has sold more than 10 million bottles. It is available through home-delivery medicine sales, drugstores, and Fuji Yakuhin’s official online store.
Fuji Arrow® A Cream for Adult Acne to Launch July 1
Fuji Yakuhin Co., Ltd. will launch Fuji Arrow® A Cream, a topical medicine, on Wednesday, July 1, 2026. It contains antibacterial and anti-inflammatory ingredients to suppress bacteria that cause adult acne and reduce inflammation.
Fuji Arrow® DZ Cool Cream Launches July 1 to Relieve Itching in Sensitive Areas
Fuji Yakuhin Co., Ltd. will launch Fuji Arrow® DZ Cool Cream, a new product in its topical medicine line, on Wednesday, July 1, 2026. The cream contains diphenhydramine hydrochloride, lidocaine, and l-menthol to relieve itching in sensitive areas while providing a cooling sensation. It will be available at drugstores and through the official online store.
Fuji Yakuhin Named to White 500 for Fifth Consecutive Year
Fuji Yakuhin Co., Ltd. has been named to the White 500 list of Excellent Health Management Corporations for the fifth consecutive year and has received Excellent Health Management Corporation recognition for seven consecutive years. Across the group, 10 companies, including Fuji Yakuhin, were recognized as Excellent Health Management Corporations 2026.
§08
Public records
GOV
National Tax Agency basic information4030001007483
Source: National Tax Agency Corporate Number Publication Site, basic three items